[Ip-health] KEI Statement on House Letter to President Trump on the Protection of Taxpayers’ Rights in Federally-Funded Inventions

Zack Struver zack.struver at keionline.org
Tue Apr 4 12:23:16 PDT 2017


​4 APRIL 2017
CONTACT: Zack Struver, zack.struver at keionline.org or +1 (202) 332-2670

In a letter sent today, Representative Lloyd Doggett, D-Texas, and 50 other
democratic members of Congress requested that President Donald J. Trump
issue guidance for the use of Bayh-Dole Act march-in rights in order to
protect taxpayer’s rights in federally-funded patented inventions.
The following statement should be attributed to James Love, Director of
Knowledge Ecology International (KEI):

“The letter from members of Congress on the need to protect taxpayer's
rights in the inventions they fund is important, timely, and directly
related to the challenge of providing affordable health care to everyone.
Federally-funded inventions are now routinely placed on the market at
extremely high prices. Astellas charges more than $350 per day for the
prostate cancer drug Xtandi, and BioGen is charging $1.125 million for the
first two years of Spinraza, which is used to treat spinal muscular atrophy
in mostly young children. The notion that the federal government will not
engage on the pricing of these products runs counter to the explicit
provisions in the Bayh-Dole Act that require inventions be made ‘available
to the public on reasonable terms.’ The President can curb high prices for
these drugs without new legislation, and without putting patients at risk.”

KEI filed the most recent march-in request with the federal government on
the prostate cancer drug Xtandi <http://keionline.org/xtandi>.

The letter is available as a PDF here
and below in plain text.

Representative Doggett’s office issued the following press release:

April 4, 2017
President Donald J. Trump
The White House
1600 Pennsylvania Avenue
Washington, D.C. 20500

Re: Use Existing Taxpayer Protection Rights Law to Lower Prescription Drug
Prices Now

Dear President Trump,

We write regarding your oft-stated commitment to bring down pharmaceutical
prices. You have said that the pharmaceutical industry is “getting away
with murder” and called drug prices “astronomical.” We urge you to use your
existing statutory authority to respond to soaring drug costs harming so
many American families.

Currently, the federal government grants companies (including foreign
companies) monopoly pricing power to overcharge American taxpayers for
life-saving medications developed through taxpayer-financed research. The
government prevents competitors from entering the market, thus removing any
market forces that might keep drugs affordable. Your Administration already
has legal authority to prevent pricing excesses by promoting competition,
while protecting taxpayer investments and addressing the failures of
government-approved monopolies. This health and taxpayer protection issue
is one that the prior Administration declined to address.

When taxpayer-funded federal research results in a new drug patent, the
National Institutes of Health (NIH) is permitted to require the patent
holder to license the federally-funded intellectual property to third
parties, under certain circumstances. This power, granted in 1980 through
the Bayh-Dole Act, authorizes federal agencies that fund private research
to retain certain rights in patented inventions.

Under 35 U.S.C. §203(a)(2), when “action is necessary to alleviate health
and safety needs which are not being reasonably satisfied” or, as noted in
35 U.S.C. §201(f), when the benefits of the patented product are not
“available to the public on reasonable terms,” the government can assert
what are sometimes called “march-in rights,” but would be better described
as “taxpayer protection rights.” By exercising these rights, the government
can encourage competition and lower prices by allowing other manufacturers
to produce and sell the taxpayer-funded drug. Unfortunately, NIH has never
utilized this taxpayer protection law.

Drug manufacturers and patients need clarity. We urge you to direct NIH to
issue public guidelines on the circumstances that will likely require it to
invoke taxpayer protection rights. Reasonable and transparent guidelines
would discourage drug price gouging and create a more competitive market
for drugs developed using tax dollars. American taxpayers should be able to
access publicly-funded medications on reasonable terms, instead of being
burdened with unreasonable prices.

Last year, NIH also refused to hold a hearing on whether to exercise its
statutory rights on Xtandi, a prostate cancer drug developed at the
University of California, Los Angeles (UCLA) through taxpayer-supported
research grants, but licensed to a Japanese company. As a result, Americans
are still paying two to four times more than consumers in other high-income
countries for a life-saving medication developed with our tax
dollars—without even the benefit of a public hearing to determine why NIH
refused to protect taxpayers.

We are confident that reasonable guidance can be developed to address price
gouging with transparency and fairness. We want pharmaceutical
manufacturers to have the certainty of clear guidelines that indicate when
taxpayer protection rights would apply, so that they can perform in a
constructive way that avoids ever necessitating use of this extraordinary
remedy. Since companies that do not engage in price gouging would not be
affected, innovation and industry partnerships with public research
institutions would not be threatened.

With adequate guidance, pharmaceutical companies should make
better-informed pricing decisions that reflect the value of the taxpayer
investment. High prescription drug prices are not limited to one treatment
or one disease. Rising prices are reflected in ballooning Medicare and
Medicaid drug budgets, and hit consumers through rising premiums, greater
cost-sharing, and the higher prevalence of high-deductible plans. With drug
prices continuing to soar and Americans continuing to struggle to access
life-saving medications, your quick use of this taxpayer protection law
will provide significant help to American families.

We look forward to your prompt response on this strategy to promote
competition, target bad actors, and protect taxpayer investments.


Lloyd Doggett
Jan Schakowsky
Rosa DeLauro
Peter Welch
Mark Pocan
John Yarmuth
Peter Visclosky
Louise Slaughter
Beto O’Rourke
Chellie Pingree
Eleanor Holmes Norton
Richard M. Nolan
Jerrold Nadler
Gwen Moore
Michelle Lujan Grisham
John Lewis
Barbara Lee
Brenda L. Lawrence
Ro Khanna
Marcy Kaptur
Priyanka Jayapal
Sheila Jackson Lee
Earl Blumenauer
Matt Cartwright
Kathy Castor
Judy Chu
David N. Cicilline
Emmanuel Cleaver II
Steve Cohen
John Conyers, Jr.
Elijah Cummings
Peter A. DeFazio
Keith Ellison
Mark DeSaulnier
Theodore E. Deutch
John Garamendi
Al Green
Raúl M. Grijalva
Luis V. Gutiérrez
Alcee L. Hastings
Grace Napolitano
Bobby Scott
Alan Lowenthal
Suzanne Bonamici
Bennie G. Thompson
José E. Serrano
Jamie Raskin
Carol Shea-Porter
Mark Takano
Karen Bass
Brian Higgins​

Zack Struver, Communications and Research Associate
Knowledge Ecology International
zack.struver at keionline.org
Twitter: @zstruver <https://twitter.com/zstruver>
Office: +1 (202) 332-2670 Cell: +1 (914) 582-1428

More information about the Ip-health mailing list